Trial Profile
A Randomized, Double-blind, Placebo-controlled in Parallel, Multicenter Phase III Trial of Recombinant Human Apo-2 Ligand for Injection Dulanermin for Injection in the Treatment of Advanced Non-small Cell Lung Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Dulanermin (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Shanghai GeBaiDe Biotechnical Co
- 23 Mar 2017 New trial record